FdaApplication
NDA 215383
Identifiers
- fda_app_no: NDA215383
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC |
| application_type | NDA |
| approval_date | 2021-08-13 |
Revenue by product
WELIREG
| Period | Revenue |
|---|---|
| Q2 2026 | $271.0M |
| Q1 2026 | $199.0M |
| Q4 2025 | $220.0M |
| Q3 2025 | $196.0M |
| Q2 2025 | $162.0M |
| Q1 2025 | $137.0M |
| Q4 2024 | $160.0M |
| Q3 2024 | $139.0M |
| Q2 2024 | $126.0M |
| Q1 2024 | $85.0M |
| Q4 2023 | $72.0M |
| Q3 2023 | $54.0M |
| Q2 2023 | $50.0M |
| Q1 2023 | $42.0M |
| Q4 2022 | $40.0M |
| Q3 2022 | $38.0M |
| Q2 2022 | $27.0M |
| Q1 2022 | $18.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| WELIREG | BELZUTIFAN | 40MG | TABLET;ORAL |
1 product